User profiles for J. Mark FitzGerald
JM FitzGeraldProfessor of Medicine, University of British Columbia Verified email at vch.ca Cited by 52395 |
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a …
JM FitzGerald, ER Bleecker, P Nair, S Korn, K Ohta… - The Lancet, 2016 - thelancet.com
Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α
monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We …
monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We …
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a …
ER Bleecker, JM FitzGerald, P Chanez, A Papi… - The Lancet, 2016 - thelancet.com
Background Eosinophilia is associated with worsening asthma severity and decreased lung
function, with increased exacerbation frequency. We assessed the safety and efficacy of …
function, with increased exacerbation frequency. We assessed the safety and efficacy of …
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
…, L Duijts, JM Drazen, JM FitzGerald… - American journal of …, 2022 - atsjournals.org
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually
updated evidence-based strategy for asthma management and prevention, which can be …
updated evidence-based strategy for asthma management and prevention, which can be …
[HTML][HTML] Mepolizumab treatment in patients with severe eosinophilic asthma
…, ID Pavord, GG Brusselle, JM FitzGerald… - New England journal …, 2014 - Mass Medical Soc
Background Some patients with severe asthma have frequent exacerbations associated with
persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled …
persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled …
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
JM FitzGerald, ER Bleecker, A Menzies-Gow… - The Lancet …, 2018 - thelancet.com
Background Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor α monoclonal
antibody that has been shown to significantly reduce asthma exacerbations and improve …
antibody that has been shown to significantly reduce asthma exacerbations and improve …
[HTML][HTML] Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma
…, L Ford, L Sher, JM FitzGerald… - New England journal …, 2018 - Mass Medical Soc
Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …
A summary of the new GINA strategy: a roadmap to asthma control
…, SJ Szefler, GWK Wong, JM FitzGerald - European …, 2015 - Eur Respiratory Soc
Over the past 20 years, the Global Initiative for Asthma (GINA) has regularly published and
annually updated a global strategy for asthma management and prevention that has formed …
annually updated a global strategy for asthma management and prevention that has formed …
[HTML][HTML] Inhaled combined budesonide–formoterol as needed in mild asthma
Background In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a
fast-acting β 2 -agonist may be an alternative to conventional treatment strategies. Methods …
fast-acting β 2 -agonist may be an alternative to conventional treatment strategies. Methods …
[HTML][HTML] Effects of an anti-TSLP antibody on allergen-induced asthmatic responses
…, D Cockcroft, J Bigler, JM FitzGerald… - … England Journal of …, 2014 - Mass Medical Soc
Background Thymic stromal lymphopoietin (TSLP) is an epithelial-cell–derived cytokine that
may be important in initiating allergic inflammation. AMG 157 is a human anti-TSLP …
may be important in initiating allergic inflammation. AMG 157 is a human anti-TSLP …
Bronchial thermoplasty for asthma
…, JD Miller, A McWilliams, JM FitzGerald… - American journal of …, 2006 - atsjournals.org
Rationale: Bronchial thermoplasty (BT) reduces the potential for smooth muscle–mediated
bronchoconstriction by reducing the mass of smooth muscle in the walls of conducting airways…
bronchoconstriction by reducing the mass of smooth muscle in the walls of conducting airways…